Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 585Unknown 198Recruiting 158Terminated 144Active not recruiting 114Not yet recruiting 59Withdrawn 55Enrolling by invitation 4Suspended 3

Sponsor Class

INDUSTRY 5OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Dermatologic 1

Conditions

Breast Neoplasms 2Melanoma 1

Interventions

Specimen Handling 11Cyclophosphamide 9Magnetic Resonance Spectroscopy 8pembrolizumab 6Cisplatin 6Bevacizumab 6Radiosurgery 5Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5venetoclax 4Vincristine 4S 1 (combination) 4Prednisone 4Leucovorin 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3fludarabine 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Rituximab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × OTHER × Paclitaxel × Clear all
NCT05751668 2026-04-07

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
98 enrolled
Breast

Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Academic and Community Cancer Research United

Phase 3 Suspended
201 enrolled 19 charts
Breast

Breast Neoplasms

NCT00278122 2013-12-10

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

University of Virginia

Phase 2 Suspended
42 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡